GlassScriptPhysician profile
Bridget K Nance
NPI 1184278863
$4,641.86
in general payments reported to CMS, 2019-2025
15 companies · $2,578 in 2025
The $2,578 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $114 · 2023: $908 · 2024: $1,042 · 2025: $2,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,643 · Travel and Lodging: $782 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,642.94 |
| Travel and Lodging | $781.58 |
| Education | $103.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $1,503.95 | 2024-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| Astrazeneca Pharmaceuticals LP | $1,013.92 | 2023-2025 | Fasenra, Tezspire, Airsupra |
| United Therapeutics Corporation | $704.86 | 2023-2025 | Tyvaso, Tyvaso |
| Regeneron Healthcare Solutions, INC. | $401.42 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.61 | 2023-2025 | Ofev |
| Glaxosmithkline, LLC. | $222.10 | 2023-2025 | Nucala, Arexvy |
| Insmed, INC. | $213.21 | 2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $106.70 | 2025 | Opsumit, Uptravi |
| Biomerieux INC | $27.27 | 2024 | Vidas Nephrocheck |
| Verona Pharma, INC. | $23.59 | 2025 | Ohtuvayre |
| Aurinia Pharma U.S., INC. | $22.82 | 2022 | |
| Merck Sharp & Dohme LLC | $22.81 | 2024 | Winrevair |
| Grifols USA, LLC | $21.40 | 2025 | Prolastin-C Liquid |
| Baxter Healthcare | $18.38 | 2023 | Hillrom - Life 2000 Ventilation System |
| Genzyme Corporation | $17.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Nance listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.